BioNTech SE annual revenue
2017
2018
2019
2020
2021
2022
2023
2024
2025
BioNTech SE Revenue Growth & History (BNTX)
BioNTech SE reported €2.87B in revenue for fiscal 2025, an increase of 4.32% from the previous fiscal year.
View full BioNTech SE company overviewBioNTech SE annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €2.87B | €118.8M | +4.32% |
| 2024 | 2024-12-31 | €2.75B | −€1.07B | −27.96% |
| 2023 | 2023-12-31 | €3.82B | −€13.49B | −77.94% |
| 2022 | 2022-12-31 | €17.31B | −€1.67B | −8.78% |
| 2021 | 2021-12-31 | €18.98B | €18.49B | +3834.63% |
| 2020 | 2020-12-31 | €482.3M | €373.7M | +344.11% |
| 2019 | 2019-12-31 | €108.6M | −€19.0M | −14.87% |
| 2018 | 2018-12-31 | €127.6M | €66.0M | +107.11% |
| 2017 | 2017-12-31 | €61.6M | — | — |
BioNTech SE quarterly revenue
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | €105.6M | −€155.2M | −59.51% |
| Q1 2026 | 2026-03-31 | €118.1M | — | — |
| Q4 2025 | 2025-12-31 | €907.4M | — | — |
| Q3 2025 | 2025-09-30 | €1.52B | — | — |
| Q2 2025 | 2025-06-30 | €260.8M | — | — |
BioNTech SE revenue growth trends
Over the last five reported fiscal years, revenue grew from €482.3M to €2.87B, a compound annual growth rate of 42.86%. BioNTech SE's latest reported quarter, Q2 2026, generated €105.6M in revenue, a decrease of 59.51% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review BioNTech SE source filings ↗Community posts
BioNTech reports longer survival in exploratory lung-cancer trial stage
BioNTech ($BNTX) and OncoC4 reported updated results for gotistobart in previously treated advanced squamous non-small cell lung cancer. Median overall survival reached 18.5 months versus 10 months with docetaxel in the non-pivotal first st ...
